[go: up one dir, main page]

KR900009095A - 합성 항원, 이의 제조방법 및 용도 - Google Patents

합성 항원, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR900009095A
KR900009095A KR1019890017933A KR890017933A KR900009095A KR 900009095 A KR900009095 A KR 900009095A KR 1019890017933 A KR1019890017933 A KR 1019890017933A KR 890017933 A KR890017933 A KR 890017933A KR 900009095 A KR900009095 A KR 900009095A
Authority
KR
South Korea
Prior art keywords
conjugate
peptide
peptides
making
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019890017933A
Other languages
English (en)
Inventor
펠저 헤르만
스튀버 베르너
훙에러 클라우스-디이터
Original Assignee
필립스타인, 헤리베르트 북
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립스타인, 헤리베르트 북, 베링베르케 아크티엔게젤샤프트 filed Critical 필립스타인, 헤리베르트 북
Publication of KR900009095A publication Critical patent/KR900009095A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음.

Description

합성 항원, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 나이세리아 메닌자이티디스(Neisseria neningitidis)의 막 단백질 및 펩타이드로 이루어진 접합물.
  2. 제1항에 있어서, 단백질이 메닌고코커스 단백질 B2인 접합물.
  3. 제1항에 있어서, 펩타이드가 100개 이하의 아미노산으로 이루어진 접합물.
  4. 제1항에 있어서, 펩타이드가 안티트롬빈 III로 부터의 펩타이드인 접합물.
  5. 제1항에 있어서, 약학제제로서의 접합물.
  6. 펩타이드 화학분야의 공정을 사용하여 단백질과 펩타이드간을 연결시킴을 특징으로 하여, 나이세리아 메닌자이티디스의 막 단백질 및 펩타이드로 이루어진 접합물을 제조하는 방법.
  7. 항체 제조를 위한 제1항에 따른 접합물의 용도.
  8. 제7항에 따른 항체의 약학 보조제 또는 진단 보조제로서의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890017933A 1988-12-07 1989-12-05 합성 항원, 이의 제조방법 및 용도 Withdrawn KR900009095A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3841091.5 1988-12-07
DE3841091A DE3841091A1 (de) 1988-12-07 1988-12-07 Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung

Publications (1)

Publication Number Publication Date
KR900009095A true KR900009095A (ko) 1990-07-02

Family

ID=6368560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890017933A Withdrawn KR900009095A (ko) 1988-12-07 1989-12-05 합성 항원, 이의 제조방법 및 용도

Country Status (8)

Country Link
EP (1) EP0372501A3 (ko)
JP (1) JPH02223599A (ko)
KR (1) KR900009095A (ko)
AU (1) AU4589289A (ko)
CA (1) CA2004810A1 (ko)
DE (1) DE3841091A1 (ko)
DK (1) DK614289A (ko)
PT (1) PT92499A (ko)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
IE912559A1 (en) * 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
CA2071088A1 (en) * 1991-06-19 1992-12-20 Emilio A. Emini Conjugates of the class ii protein of the outer membrane of neisseria meningitidis and of hiv-1 related peptides, and vaccines containing same
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP4738339B2 (ja) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群についての液体ワクチン
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
SG164344A1 (en) 2005-02-18 2010-09-29 Novartis Vaccines & Diagnostics Srl Immunogens from uropathogenic escherichia coli
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
UA95237C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
EP2308505A3 (en) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
DK2004225T3 (da) 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
US8956625B2 (en) 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2685506A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
RU2536248C2 (ru) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
JP6084631B2 (ja) 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
MX2014010011A (es) 2012-02-24 2014-09-08 Novartis Ag Proteinas y composiciones de pilus.
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102139959B1 (ko) 2012-04-26 2020-08-04 노파르티스 아게 항원 및 항원 조합물
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
HRP20211288T1 (hr) 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
MX373277B (es) 2014-02-28 2020-05-20 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
PE20181158A1 (es) 2015-12-04 2018-07-19 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
IL296165B2 (en) 2016-10-07 2023-10-01 Enterome S A Immunogenic compounds for cancer treatment
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
HUE060791T2 (hu) 2018-04-11 2023-04-28 Enterome S A Antigén peptidek rák megelõzésére és kezelésére
JP7446279B2 (ja) 2018-07-19 2024-03-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乾燥多糖を調製するための方法
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US12521443B2 (en) 2019-05-10 2026-01-13 Glaxosmithkline Biologicals Sa Conjugate production
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
DK4021487T5 (da) 2019-11-15 2024-07-29 Enterome S A Antigene peptider til forebyggelse og behandling af b-celle malignitet
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
IL302362A (en) 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
CN119522232A (zh) 2022-03-31 2025-02-25 恩特姆生物科学公司 用于预防和治疗癌症的抗原肽
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250169621A (ko) 2023-04-14 2025-12-03 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289110A3 (en) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Conjugate malaria vaccine

Also Published As

Publication number Publication date
PT92499A (pt) 1990-06-29
DK614289A (da) 1990-06-08
DE3841091A1 (de) 1990-06-13
JPH02223599A (ja) 1990-09-05
EP0372501A2 (de) 1990-06-13
DK614289D0 (da) 1989-12-06
AU4589289A (en) 1990-06-14
CA2004810A1 (en) 1990-06-07
EP0372501A3 (de) 1990-10-10

Similar Documents

Publication Publication Date Title
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
RU94040386A (ru) Синтетический пептид, синтетический липопептид, иммуногенный коньюгат, вектор, диагностический реагент, метод определения инфекций, антитета, способ получения олигомера, синтетическая вакцина против haemophilus influenzae, защищенный полисахарид
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
KR900013979A (ko) 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역
KR910016343A (ko) 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
GB9215780D0 (en) Peptide compounds
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
SE8205313L (sv) Antigen-proteinkomplex for blockering av allergiska reaktioner samt sett for framstellning derav
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
KR910019641A (ko) 사람 유두종 바이러스(hpv) 18의 단백질상의 혈청 반응성 에피토프
DE69114339T2 (de) Verfahren zur Identifizierung oder Bestimmung von Proteinen und Verwendungen dazu.
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
Watts et al. Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili
Gitlin et al. A comparison of the peptides released from related rabbit antibodies by enzymatic hydrolysis
KR900004935A (ko) 슈도 모나즈 아에루기노사의 지질단백질 i(ompi)
JPS6470498A (en) Synthetic peptide and antibody thereto
Denduchis et al. Immunochemistry of sheep anterior lens capsule
ATE116660T1 (de) Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
AU8100291A (en) Pancreas-elastasis-1-specific antibody, a process for obtaining it and a test kit containing such antibodies
KR890006253A (ko) 가금류내의 E.coli septicaemia에 대한 백신

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19891205

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid